Greg Parekh is a Founder and Managing Partner of New Rhein, a Philadelphia based life sciences venture capital and private equity firm. Before launching New Rhein in 2011, Greg ran the Mergers & Acquisitions department for Novartis AG based in Basel Switzerland from 2004 to 2010 and led the integration planning for Alcon, its largest acquisition. During his time at Novartis, Greg helped execute over 20 transactions with a total deal value of more than $70 billion. Prior to joining Novartis, Greg headed Deutsche Bank’s European Healthcare Group in London from 1998 to 2004. Greg started his career in New York in 1994 as an associate and VP at Bear Stearns’ newly formed Life Sciences group.

Greg has served as a director for several of New Rhein’s portfolio companies including Novagali Pharma, SA (a Paris, France based ophthalmology company), Biocartis NV (a Belgian oncology diagnostics company, for which Greg also served as ad-interim Chief Executive Officer from 2011 to 2013), Chase Pharmaceuticals Inc. (an Irvine, CA based Alzheimer’s drug company), Softhale NV (a Belgian respiratory pharma company), Neuraptive Therapeutics, Inc. (a Philadelphia based nerve repair drug company), Butterfly Medical Ltd. (an Israeli Urology device company) and Alveus Inc. (a cardio-metabolic pharma company). In addition to his role at New Rhein, Greg is a FASCO member of the American Society of Clinical Oncology (ASCO) and served as director of CancerlinQ, ASCO’s wholly-owned big-data digital healthcare platform.

Greg holds a Ph.D. in Economics from Northwestern University, an executive leadership program certificate from Harvard Business School and a dual-major B.A. in Economics and Political Science from the University of Rochester (magna cum laude). Greg lives in Brussels Belgium.

Raj Kannan is a seasoned biopharmaceutical executive with over three decades of global leadership experience across the biotech and pharmaceutical industries. He has successfully built and scaled high-performing teams and organizations, led major product launches across cardio-vascular, respiratory, and rare diseases, and created significant value through strategic M&A and operational execution.

Raj most recently served as Chief Executive Officer of I-Mab, a global biotech company focused on immuno-oncology, where he led the company through a period of transformation and strategic prioritization. Prior to I-Mab, he was CEO of Aerie Pharmaceuticals, where he oversaw the company’s acquisition by Alcon, and Chiasma, Inc., where he guided the company through a successful commercial launch and eventual merger with Amryt Pharma.

Raj held key leadership roles at Boehringer-Ingelheim and at Merck KgAA. Raj holds a Bachelor of Science in Chemistry and an MBA in Marketing.

Jacob Jeppesen was formerly the Therapeutic Area Head of Type 2 Diabetes and Cardiovascular Disease Research at Novo Nordisk. He oversaw a broad portfolio of research projects, from early discovery to clinical candidates. As Vice President of Type 2 Diabetes and Cardiovascular Disease Research he was leading teams responsible for biology and technology expertise in skeletal muscle, adipose tissue, liver, cardiac, and vascular biology.

Jacob began his career at Novo Nordisk in 2014. From 2017 to 2020, he joined the initial expansion into Boston, MA, as Scientific Director, with affiliate appointments at MIT and Whitehead Institute as visiting scientist, before assuming the role of Director and Head of Diabetes & Metabolism.
Jacob received a PhD from the University of Copenhagen and later became an Associate Professor.

Xiao-Ping Dai has over 24 years of Biopharma and Biotech industry experience. Her expertise encompasses a broad spectrum of biopharmaceutical product development, process development and manufacturing, including end-to-end CMC leadership from discovery to commercialization for biologics, cell and gene therapies, small molecules, and oligonucleotides.

Xiao-Ping participated in of the commercial development and success of Opdivo, Yervoy, Reblozyl and Izervay.

She was the CTO and SVP at IVERIC Bio, and led the late-stage CMC development, NDA filing and commercial launch of Izervay. Prior to that, Xiao-Ping was Chief Technologist at WuXi Advanced Therapy supporting acceleration of technical platform development and serving CGT clients following her role as Sr. Director of Biologics Development and Manufacturing at Celgene Corporation.

Xiao-Ping also had over 12 years’ successful functional and cross-functional leadership and technical experience in Biologics Development and Manufacturing at Medarex / BMS, and Regeneron Pharmaceuticals.

Brian Bloomquist began his career in the Obesity group at Bayer Pharmaceuticals where he spent 11 years, having multiple leadership roles and leaving as Principal Research Scientist II. Brian then joined Eli Lilly, where he held key leadership positions in the External Innovation group for over 18 years and was involved in the establishment of multiple research collaborations and the licensing or acquisition of numerous programs, leaving as Vice President of Lilly Diabetes, Obesity, and Complications External Innovation. He received his PhD in Molecular Biology from Purdue University and completed his postdoctoral fellowship at the John Hopkins University School of Medicine.

Erik started his career at KPMG, Audit Department.
He subsequently held various Finance positions with increasing responsibilities in various industries.
He was Senior Controller at J&J (Tibotec), Head of Finance at Parkwind (now known as Jeranex) and Director of Finance at invoX Pharma.

Erik has a degree in Applied Economics and a Master in Corporate Tax and has a wealth of experience in pharma related project reporting, budgeting process, and group tax structure.

Dr. Ivan Gergel joined New Rhein as a Managing Partner and CMO in 2017. Ivan is a medical doctor and experienced global pharmaceutical R&D executive whose successes to date include 14 drug approvals. Ivan has held senior leadership positions in several U.S. companies and overseen teams in the development, approval, and commercialization of numerous new medicines.

Prior to joining New Rhein, from 2014 to 2017 Ivan was CMO and Head of Drug Development for Nektar Therapeutics, Inc. From 2008 to 2014, Ivan served as Executive VP and Chief Scientific Officer of Endo Health Solutions. Ivan held various roles at Forest Laboratories, Inc. from 1998 to 2008, including Senior VP of R&D and President of the Forest Research Institute. From 1989 to 1998, he worked for SmithKline Beecham in the UK and the U.S. Ivan received his MD from the Royal Free Medical School, University of London, and his MBA from the Wharton School of the University of Pennsylvania. Ivan is a member of the Royal College of Psychiatrists and a fellow of the Faculty of Pharmaceutical Medicine of the UK College of Physicians. He presently serves on the board of Fund 18 portfolio company Neuraptive Therapeutics, Inc., and Butterfly Medical Ltd.

Ivan was the former board director of Neurotrope Inc. He has served on the boards of Corium International Inc., Realm Therapeutics, PA BIO,  and of the PhRMA Foundation. Ivan served as a member of the Science and Regulatory Committee of PhRMA. He lives with his wife Ann in Malvern, Pennsylvania.  They have three sons who also live close to them.  Ivan plays tennis and misses playing cricket.

Ameet Nathwani is a UK-trained physician and cardiologist with over three decades of leadership in the global biopharmaceutical industry. He is currently CEO of Dewpoint Therapeutics, a Boston-based biotechnology company pioneering the role of biomolecular condensates in disease pathobiology and leveraging this to discover novel therapeutics. Under his leadership, Dewpoint has built a unique discovery platform that integrates advanced biology and AI to create novel condensate-modifying drugs (c-mods) that unlock new therapeutic pathways.

The company has formed strategic discovery alliances with Bayer and Novo Nordisk, licensed early programs in cardiovascular disease and neurodegeneration to Bayer and MTPC respectively, and developed a robust pipeline in oncology targeting iconic, difficult-to-drug molecules such as beta-catenin and MYC.

Previously, Dr. Nathwani served on the Executive Committee of Sanofi as Chief Medical Officer and Chief Digital Officer, where he oversaw global development, safety, patient outcomes, and digital transformation across the discovery, development and commercial value chain. Before Sanofi, he held global senior leadership positions at Novartis, including Head of Medical Affairs, Head of the Critical Care Business Unit, and Head of CardioMetabolic Development.

Over his career, he has led more than 20 global development programs and contributed to 16 product approvals—five of which became blockbusters—including Coreg, Diovan (and its derivatives), Galvus, and Entresto. He is widely recognized for his leadership in cardio-metabolic drug development, digital health, and the application of AI and real-world evidence in biopharma innovation.

Carlo has an extensive experience as an international Operations senior executive with global technical, operational, and P&L responsibilities.  He has deep expertise in designing and operating global supply chains in complex regulatory environments, leading accretive M&A activity, and devising and executing value creating strategies in global markets. He currently serves on the board of several pharma and CDMO companies, and advises Pharma, Generics and CDMO companies, as well as PE firms.

In May 2020, Carlo joined Operation Warp Speed/Federal Covid Response, the USG initiative to support acceleration of development and supply of Covid-19 vaccines and therapeutics, as the lead advisor for Manufacturing and Supply Chain.  He has collaborated with the sponsors, suppliers and CDMOs to ensure the fast scale up of manufacturing and distribution for the US.

In Carlo’s most recent corporate position, he was Executive VP of Operations at Teva Pharmaceuticals Inc.  Carlo retired from this position at the beginning of 2020.

Before joining Teva Pharmaceuticals Inc in 2012, Carlo was the President Technical Operations and Global Support Functions for Bristol Myers Squibb between 2004 and 2011.

Carlo has a Doctor’s degree in Chemical Engineering from the University of Naples, and lives in New Jersey with his wife Leila.

E. Garrett Ingram is a leading biotech executive with extensive expertise in global medicines and market access. She joined Cipla in June 2019 as Chief Commercial Officer and Head of Cipla Therapeutics, driving the transformation of biotech and specialty platforms. With over twenty years of experience in pharmaceuticals, biotech, and device marketing, Garrett has a proven track record of leadership, successfully guiding organizations through turnarounds and delivering profitability.

In July 2020, Garrett was appointed President & CEO of Cipla Therapeutics, Inc., leading the institutional specialty business. In 2023, she was named one of the Top 25 Healthcare Technology Leaders of NJ. Before Cipla, she served as Chief Marketing Officer at MannKind Corporation, delivering share and net profit growth and leading strategies for new compounds and brand plans.

Garrett has held senior roles at Dexcom, Sanofi, Bristol Myers Squibb, and Novo Nordisk, where she led market access strategies, managed launches, and developed innovative partnerships like the Diabetes Prevention and Control Alliance. She has extensive experience in marketing, launch, managed care, health economics, and multi-product lifecycle management with Pfizer, Pharmacia/Upjohn, and healthcare provider organizations.

Garrett holds a Bachelor of Science degree from East Carolina University and a master’s degree in public health from the University of South Carolina. She has completed executive leadership programs at Wharton School of Business and dedicates her free time to mentorship and community impact. She is currently a board member of Alveus Therapeutics and Cipla Therapeutics, Inc.

Steve Krognes is a professional board member in the biotech and life science sector. He currently serves as a Director at Denali Therapeutics, Guardant Health, argenx and Pliant Therapeutics, all publicly listed companies, as well as ClavystBio, a privately held company in Singapore. Previously, he worked 7 years as CFO of Denali Therapeutics, 6 years as CFO of Genentech and 6 years as global head of M&A at Roche.

At Denali, Steve built the finance, IT and site organizations, and led the company’s IPO and capital raising efforts. At Genentech, Steve led the integration of Roche and Genentech, chaired the Genentech Access to Care Foundation and represented Genentech on the Board and Executive Committee of the California Life Science Association. At Roche, under Steve’s leadership, the M&A team executed more than 30 transactions worldwide, and he personally led the acquisition and subsequent integration of Genentech.

Prior to that, Steve worked as an investment banker at Goldman Sachs, a management consultant at McKinsey, and as a venture capitalist in Scandinavia. Steve holds an M.B.A. from Harvard Business School, and a B.S. in Economics from the Wharton School of the University of Pennsylvania.

Steve grew up in Norway and is a second lieutenant in the Royal Norwegian Air Force, and speaks Norwegian, French, and conversational German. Steve lives in Cannes (France) and San Francisco (USA) with his family.